Retatrutide Research
Who Makes Retatrutide? Eli Lilly and Development
Retatrutide is developed by Eli Lilly and Company under the internal code LY3437943. It is the successor to Lilly's incretin programme that produced dulaglutide and tirzepatide. All Phase 1–3 clinical trials of retatrutide are sponsored by Eli Lilly.
Key facts
- Developer
- Eli Lilly and Company
- HQ
- Indianapolis, USA
- Internal code
- LY3437943
- Related products
- Tirzepatide (Mounjaro/Zepbound), dulaglutide (Trulicity)
Lilly's incretin lineage
Lilly's incretin pipeline began with exenatide-era work, matured with dulaglutide, then tirzepatide, and now retatrutide. Each step increased receptor complexity — from single GLP-1 to dual GIP/GLP-1 to triple GIP/GLP-1/glucagon.
Extended research context
The Retatrutide Research deep dive
Deep dive: how the triple-agonist scaffold was engineered
Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance — the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.
The TRIUMPH Phase 3 programme in context
TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator — FDA, EMA, or MHRA — has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.
How retatrutide differs from tirzepatide and semaglutide at the mechanism level
Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press — but the pharmacology is more nuanced than the label implies.
Research applications
- ▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
- ▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
- ▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
- ▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
- ▸Reference material for teaching incretin pharmacology in university-level courses
Handling checklist
- ✓Store lyophilised vials at −20 °C; protect from light and humidity
- ✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
- ✓Once reconstituted, store at 2–8 °C and use within 28 days
- ✓Verify batch CoA — HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
- ✓Do not administer to humans or animals — research use only
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Confusing retatrutide with tirzepatide in supplier catalogues
Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.
✗ Using tap or filtered water for reconstitution
Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water — never lab DI water.
✗ Storing reconstituted solution at room temperature
Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is retatrutide the same molecule as LY3437943?
- What is the correct spelling: retatrutide or retatrutid?
- Is retatrutide a GLP-1 drug?
- Which company makes retatrutide?
- When will retatrutide be FDA approved?
- Is retatrutide legal in the UK?
Frequently asked questions
- Does anyone else make retatrutide?
- Only Eli Lilly holds the development programme. Research-grade material from other suppliers is not manufactured by Lilly.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- RefEli Lilly investor materialsinvestor.lilly.com
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05869903) — Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05882045) — Retatrutide in obesity + T2DMclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05936151) — Retatrutide + established CVDclinicaltrials.gov
- PubMedJastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity — NEJM 2023 (PMID 37356472)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock et al., Retatrutide in adults with T2D — Lancet 2023 (PMID 37356473)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Retatrutide (CID 156588324)pubchem.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More Retatrutide Research articles
- Retatrutide Half-Life and Pharmacokinetics (Research Data)Retatrutide half-life is approximately 6 days, supporting once-weekly research administration. Pharmacokinetics from published Phase 1 trial data.
- Retatrutide CAS Number and Chemical IdentityRetatrutide CAS number, PubChem CID, molecular formula and chemical identifiers. Reference chemistry data for the LY3437943 investigational peptide.
- How Retatrutide Differs From First-Generation IncretinsRetatrutide differs from first-generation incretins (exenatide, liraglutide) by activating three receptors and using albumin binding for a longer half-life.
- Retatrutide Storage and Stability (Research Handling)Retatrutide storage: lyophilised vials stable at 2–8°C, reconstituted material for short-term refrigerated use. Handling guidance for research settings.
- Retatrutide Molecular Weight ExplainedRetatrutide molecular weight is approximately 4,731 Da — a 39-residue peptide with fatty-acid conjugation. Why molecular weight matters for peptide research.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- GHK-Cu (Copper Peptide)Copper Peptides Explained: The GHK-Cu Family
- TB-500 (Thymosin β4 fragment)BPC-157 and TB-500: How They Differ
- BPC-157 (Pentadecapeptide)BPC-157 in Tendon and Ligament Research
- CJC-1295 & IpamorelinCJC-1295 and Ipamorelin Storage Handling
- Peptide ReferenceHow Peptides Are Made: Synthesis Explained
- Bacteriostatic WaterWhy Bacteriostatic Water Is Used to Reconstitute Peptides